Press Releases

Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

Sol-Gel Technologies Announces Management Realignment

Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream